Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03543878 · ClinicalTrials.gov registry record · NA
Stimulating Neural Activity to Improve Blood Flow and Reduce Amyloid: Path to Clinical Trials
A NA study, sponsored by Emory University.
- Completed
- Registry status
- NA
- Development phase
- 10
- Enrollment target
NCT03543878 is a NA study that has completed, run by Emory University. The registered enrollment target is 10 participants.
The verdict
NCT03543878, a NA study, has completed, sponsored by Emory University.
- COMPLETED
- Registry status
- NA
- Development phase
- 10 participants
- Enrollment target
Study Summary
Alzheimer's disease is characterized by the accumulation of toxic proteins in the brain. Mechanisms to remove these proteins have been the target of many drug trials. This study is designed to use a device to entrain brain waves to a specific frequency to see if rodent research can be replicated in humans with mild cognitive impairment. Ten participants will be recruited from the Emory Alzheimer's Disease Research Center (ADRC) database and assigned to either treatment for 8 weeks or treatment for 4 weeks. This latter group will serve as the control group (4 weeks no treatment, 4 weeks treatment). It is hypothesized that exposure to the gamma oscillations (Flicker) will clear toxic proteins from the brain and increase cerebral blood flow.
Interventions
- DEVICE Flicker
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2018-11-16 |
| Est. Completion | 2020-02-10 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03543878
The ClinicalTrials.gov registry entry for NCT03543878 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Emory University, which has 1,208 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Flicker is the first listed.
NCT03543878 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03543878 about?
NCT03543878 is a clinical study titled "Stimulating Neural Activity to Improve Blood Flow and Reduce Amyloid: Path to Clinical Trials". Alzheimer's disease is characterized by the accumulation of toxic proteins in the brain. Mechanisms to remove these proteins have been the target of many drug trials. This study is designed to use a device to entrain brain waves to a specific frequency to see if rodent research can be replicated in ...
What is the current status of trial NCT03543878?
This trial is currently completed. It is a NA study. The enrollment target is 10 participants. The study started on 2018-11-16. Estimated completion is 2020-02-10.
What interventions are being tested in trial NCT03543878?
The interventions under investigation include: Flicker (DEVICE).
Who is sponsoring clinical trial NCT03543878?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.